By Hilary Rosselot
Asuragen Presents During the 2022 Industry Updates Keynote at the 18th International Fragile X Conference
Stela Filipovic-Sadic, a manager of Research & Development at Asuragen, presented Asuragen’s molecular testing capabilities for FMR1 and Fragile X, and showed how new technologies drive progress in the field. Asuragen has been a part of the Fragile X community for years. Their tests have been used to help patients, clinicians, and researchers aid in diagnosis, screen potential carriers, stratify risk of Fragile X being passed onto the next generation, and connect patients to new therapies.
Learn more about Asuragen by watching their 2022 Industry Updates presentation or visiting their website.
Check out the Behind the Mystery of Fragile X Syndrome segment sponsored by Asuragen.
Developing the Fragile X Syndrome-Health Index (FXS-HI): A Caregiver-Reported Outcome Measure
The Center of Health and Technology’s (CheT) Outcomes Division is conducting caregiver interviews to learn about and determine the most important symptoms to individuals with FXS to create an outcome measure for FXS.
FMR1 CGG Repeats and Stress Influence Self-Reported Cognitive Functioning in Mothers
Researchers at the University of Wisconsin looked at the relationship and influence of FMR1 CGG repeats and stress on self-reported cognitive functioning in mothers.